FROM THE EDITORS
Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.
For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.
![]() |
![]() |
Katie Newlin, RN, MSN, AGPCNP-BC Washington University in St. Louis/Siteman Cancer Center
|
Lisa Salem, MSN, FNP-BC, AOCNP Washington University in St. Louis/Siteman Cancer Center |
Resources
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
HER2 Testing in Breast Cancer - 2023 Guideline Update
Real-World Survival Outcomes by Risk Features in Patients with HR+, HER2− Early Breast Cancer in the US
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)
Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
News & Literature Highlights